Protagonist Therapeutics Showcases Lasting Success for New Oral Psoriasis Pill

Newark, Saturday, 28 March 2026.
Protagonist Therapeutics revealed strong one-year data for ICOTYDE. As the first oral pill of its kind, this FDA-approved treatment is poised to disrupt the lucrative injectable psoriasis market.